Lv3
390 积分 2022-11-23 加入
Animal models for development of anti-obesity drugs in the age of GLP-1 agents
24天前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
1个月前
已完结
Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy
1个月前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
1个月前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
1个月前
已完结
682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
2个月前
已完结
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model
2个月前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
2个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
2个月前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
4个月前
已关闭
皖公网安备34019202002308
